A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
04 2019
Historique:
received: 08 09 2018
revised: 01 11 2018
accepted: 02 02 2019
pubmed: 9 2 2019
medline: 4 6 2020
entrez: 9 2 2019
Statut: ppublish

Résumé

In men with localized prostate cancer who are undergoing radical prostatectomy (RP), it is uncertain whether their systemic hormonal environment is associated with outcomes. The objective of the study was to examine the association between the circulating steroid metabolome with prognostic factors and progression. The prospective PROCURE cohort was recruited from 2007 to 2012, and comprises 1,766 patients with localized prostate cancer who provided blood samples prior to RP. The levels of 15 steroids were measured in plasma using mass spectrometry, and their association with prognostic factors and disease-free survival (DFS) was established with logistic regression and multivariable Cox proportional hazard models. The median follow-up time after surgery was 73.2 months. Overall, 524 patients experienced biochemical failure and 75 developed metastatic disease. Testosterone and androsterone levels were higher in low-risk disease. Associations were observed between adrenal precursors and risk of cancer progression. In high-risk patients, a one-unit increment in log-transformed androstenediol (A5diol) and dehydroepiandrosterone-sulfate (DHEA-S) levels were linked to DFS with HR of 1.47 ( In men with localized prostate cancer, our data suggest that the preoperative steroid metabolome is associated with the risk of recurrence of high-risk disease. The associations of adrenal androgens with progression of localized high-risk disease could help refine hormonal strategies for these patients.

Sections du résumé

BACKGROUND
In men with localized prostate cancer who are undergoing radical prostatectomy (RP), it is uncertain whether their systemic hormonal environment is associated with outcomes. The objective of the study was to examine the association between the circulating steroid metabolome with prognostic factors and progression.
METHODS
The prospective PROCURE cohort was recruited from 2007 to 2012, and comprises 1,766 patients with localized prostate cancer who provided blood samples prior to RP. The levels of 15 steroids were measured in plasma using mass spectrometry, and their association with prognostic factors and disease-free survival (DFS) was established with logistic regression and multivariable Cox proportional hazard models.
RESULTS
The median follow-up time after surgery was 73.2 months. Overall, 524 patients experienced biochemical failure and 75 developed metastatic disease. Testosterone and androsterone levels were higher in low-risk disease. Associations were observed between adrenal precursors and risk of cancer progression. In high-risk patients, a one-unit increment in log-transformed androstenediol (A5diol) and dehydroepiandrosterone-sulfate (DHEA-S) levels were linked to DFS with HR of 1.47 (
CONCLUSIONS
In men with localized prostate cancer, our data suggest that the preoperative steroid metabolome is associated with the risk of recurrence of high-risk disease.
IMPACT
The associations of adrenal androgens with progression of localized high-risk disease could help refine hormonal strategies for these patients.

Identifiants

pubmed: 30733309
pii: 1055-9965.EPI-18-1002
doi: 10.1158/1055-9965.EPI-18-1002
doi:

Substances chimiques

Gonadal Steroid Hormones 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

701-706

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Eric Lévesque (E)

Centre Hospitalier Universitaire (CHU) de Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada. eric.levesque@crchudequebec.ulaval.ca chantal.guillemette@crchudequebec.ulaval.ca.

Patrick Caron (P)

CHU de Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada.

Louis Lacombe (L)

Centre Hospitalier Universitaire (CHU) de Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada.

Véronique Turcotte (V)

CHU de Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada.

David Simonyan (D)

Statistical and Clinical Research Platform, CHU de Québec Research Centre, Québec, Canada.

Yves Fradet (Y)

Centre Hospitalier Universitaire (CHU) de Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada.

Armen Aprikian (A)

McGill University Health Centre, McGill University, Faculty of Medicine, Québec, Canada.

Fred Saad (F)

Centre Hospitalier de l'Université de Montréal, Faculty of Medicine, Université de Montréal, Québec, Canada.

Michel Carmel (M)

Université de Sherbrooke, Faculty of Medicine, Québec, Canada.

Simone Chevalier (S)

McGill University Health Centre, McGill University, Faculty of Medicine, Québec, Canada.

Chantal Guillemette (C)

CHU de Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada. eric.levesque@crchudequebec.ulaval.ca chantal.guillemette@crchudequebec.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH